{"brief_title": "Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)", "brief_summary": "This study is a multicenter, open-label, postmarketing surveillance study. The substudy will collect information on BMD in adolescents and young adults with GHD or Turner syndrome who are completing GH treatment for statural indications.", "condition": "Turner Syndrome", "study_pop": "\n      ", "sampling_method": "Non-Probability Sample", "criteria": "Inclusion Criteria: - Bone age of at least 15 years for girls or at least 16 years for boys within 6 months of obtaining the DXA scan - Previous enrollment in the NCGS core study, 85-036 - Tanner Stage 4 or greater - Either spontaneous or induced puberty - Subjects who plan on terminating GH treatment for statural purposes for one or more of the following reasons: epiphyseal fusion, slowing growth rate indicates that near adult height has been reached, or satisfied with current height Exclusion Criteria: - Current therapy with a non Genentech GH product - Pregnancy (to avoid exposure to low levels of radiation from DXA scanners) - Bilateral hip replacement - Weight >130 kg (286 lb.)", "gender": "All", "minimum_age": "N/A", "maximum_age": "17 Years", "healthy_volunteers": "No", "id": "NCT00097526.xml"}